Economic Outcomes of Colfosceril Palmitate Rescue Therapy in Infants Weighing 1250g or More with Respiratory Distress Syndrome
- 5 Downloads
An analysis of the economic data from a l11ulticClltrc, randomised, placebocontrolled clinical trial of colfosccri l palmitate in infants with neonatal respiratory distress syndrome (NRDS) and birthweights of I 250g or more is presented.
Two 5 ml/kg (67.5 mglkg) doses of a synthetic surfactant (co!fosceri! palmitate) or air placebo were administered to 1237 infants who were receiving mechanical ventilation and had an arterial/alveolar oxygen tension ratio of less than 0.22. In addition to the clinical end-points for safety and efficacy. data were collected on length of hospital stay. days in the neonatal intensive care unit, days on mechanical ventilation. days on oxygen. and hospital charges until the child reached 1-year adjusted age. One-year adjusted age is attained when the time elapsed since binh is equal to 365 days plus the number of days of prematurity.
Rescue treatment with synthetic surfactant therapy has been shown to reduce the incidence of complications ofNRDS. Growth and development of infants who received colfosceril palmitate therapy in the study and survived to 1-year adjusted age were equivalent to those of the survivors in the air placebo group. For the cohort of treated infants, colfosceril palmitate reduced the avemge length of stay at 2 levels of care needed during both the initial hospitalisation (it reduction of 8 days overall and 5 days in intensive care) and all first year hospitalisations (a reduction of 9 days overall and 5 days in intensive care). Total hospital charges for the initial hospitalisation and through I-year adjusted age for a hypothetical cohort of 100 infants treated with colfosceril palmitate were less than those for a comparable cohon in the air placebo group.
The results wou ld, therefore, suggest that rescue therapy with colfosceril palmitate in infants with NRDS and binhweighlsover [250g can result in substantial reductions in hospital resource utilisation and charges in addition to the clinical benefits associated with its use.
KeywordsPalmitate Neonalal Intensive Care Unit Hospital Charge Initial Hospitalisation Synthetic Surfactant
Unable to display preview. Download preview PDF.
- 3.The Osiris Collaborative Group. Early versus delayed neonatal administrdtion of a synthetic surfactant — the judgement of OSIRIS. Lancet 1992; 340: 1363-9Google Scholar
- 4.Combet A, Bucciarelli R, Gotdlrnln S, et al. Decreased monality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pcdiatr 1991; 118: 277–84Google Scholar
- 5.Kitzhabcr J. The Oregon Health Plan. Salem: Oregon State Scnate. 1992Google Scholar
- 6.Onturio Ministry of Health. Guidelines for preparation of economic analyses tObe included in submision to drug programs branch for listing in the Ontario Drug Benefit Formulary/Comparative Drug Index. Toronto: Ministry of Health, 1991Google Scholar
- 8.Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee, including submissions involving economic analyses. Canberra: Department of Health, Housing, and Community Services, 1992Google Scholar
- 9.Drummond M, Smith GT, Wells N. Economic evaluation in the development of medicines. London: Office of Health Economics, 1988Google Scholar
- 10.Backhouse M, Backhause R, Edey S. Economic evaluation bibliography. Health Econ 1992; 1 Suppl.: 1–236Google Scholar
- 17.Merrill TA, Hallman M, Vaucher Y, et al. Impact of surfactant treatment on cost of neonatal intensive care: a cost-benefit analysis. J Perinatol 1991; 10: 416–9Google Scholar
- 20.Maniscalco WM, Kendig JW, Shapiro DL. Surfactant replacement therapy: impact On hospital charges for premature infants with respiratory distress syndrome. Pediatrics 1989; 83: 1/6/2012Google Scholar
- 22.Sauve R. Developmental outcome at one year of infants treated with Exosurf Neonatal. In: Long W, Tilson H, editors. Proceedings of the Exosurf Neonatal investigatOr’s meeting: 1991 Nov 13-14. Langhorne: Adis International, 1992Google Scholar
- 23.National Center for Health Statistics. Annual summary of binhs, marriages, divorces and deaths: United States 1992Google Scholar
- 26.Finkler S. The distinction between Costs and charges. Ann Intern Mcd 1982; 96: 102–9Google Scholar
- 27.Yamaguchi K. Event history analysis. Newbury Park CA: Sage Publications, 1991Google Scholar
- 28.Crystal S, Sambamoonhi U, Merzal C. Estimating the per-case cost of AIDS care. Presented at the APHA Annual Meeting: 1992 Nov 8-12: WashingtonGoogle Scholar
- 29.Markson L, McKee L, Mauskopf J, et al. Medicaid expenditures for AIDS diagnosis, mid-illness, and death. Presented at the APHA Annual Meeting; 1992 Nov 8-12: WashingtonGoogle Scholar
- 30.Drummond M, Vella S, Backhouse M, et al. Cost-effectiveness of zidovudine therapy for people wilh AIDS: results from long-term follow-up. Presented at the 7th International AIDS Conference: 1991 Jun 16-21: FlorenceGoogle Scholar
- 31.Eidelman A. Economic consequences of surfactant therapy. J Pcrinatol 1993; 13: 137–9Google Scholar